557 related articles for article (PubMed ID: 28499452)
1. Current status and perspectives of patient-derived xenograft models in cancer research.
Lai Y; Wei X; Lin S; Qin L; Cheng L; Li P
J Hematol Oncol; 2017 May; 10(1):106. PubMed ID: 28499452
[TBL] [Abstract][Full Text] [Related]
2. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
[TBL] [Abstract][Full Text] [Related]
3. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Veeranki OL; Tong Z; Mejia A; Verma A; Katkhuda R; Bassett R; Kim TB; Wang J; Lang W; Mino B; Solis L; Kingsley C; Norton W; Tailor R; Wu JY; Krishnan S; Lin SH; Blum M; Hofstetter W; Ajani J; Kopetz S; Maru D
Dis Model Mech; 2019 Dec; 12(12):. PubMed ID: 31732509
[TBL] [Abstract][Full Text] [Related]
4. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
5. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
6. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
7. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
8. Method for Generating a Patient-Derived Xenograft Model of CLL.
Chen SS
Methods Mol Biol; 2019; 1881():165-171. PubMed ID: 30350205
[TBL] [Abstract][Full Text] [Related]
9. T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor.
Lee YS; Kim TS; Kim DK
BMC Cancer; 2011 Jun; 11():225. PubMed ID: 21649881
[TBL] [Abstract][Full Text] [Related]
10. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
Okada S; Vaeteewoottacharn K; Kariya R
Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
[TBL] [Abstract][Full Text] [Related]
11. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
12. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
13. Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review.
Tanaka T; Nishie R; Ueda S; Miyamoto S; Hashida S; Konishi H; Terada S; Kogata Y; Sasaki H; Tsunetoh S; Taniguchi K; Komura K; Ohmichi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502278
[TBL] [Abstract][Full Text] [Related]
14. Creation of PDX-Bearing Humanized Mice to Study Immuno-oncology.
Yao LC; Aryee KE; Cheng M; Kaur P; Keck JG; Brehm MA
Methods Mol Biol; 2019; 1953():241-252. PubMed ID: 30912026
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
[TBL] [Abstract][Full Text] [Related]
16. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
18. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
19. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
Front Immunol; 2021; 12():607282. PubMed ID: 33854497
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]